Home Alzheimer’s Disease Data from Phase IIb AIPAC Trial of Eftilagimod Alpha Shows Promise

Data from Phase IIb AIPAC Trial of Eftilagimod Alpha Shows Promise

Positive data from the randomized phase IIb AIPAC clinical trial of eftilagimod alpha (efti, LAG-31g, or IMP321) and paclitaxel (Abraxane) in HER2-negative, HR-positive metastatic breast cancer (MBC) was announced by Immutep.

The multicenter, placebo-controlled, double-blind study is evaluating eftilagimod alpha in combination with paclitaxel in a cohort of 277 patients with MBC to try and boost the T-cell immune responses against tumors.

“I am pleased to see this innovative chemo-immunotherapy approach in AIPAC is well tolerated by patients, while showing a numerically (non-significant) higher progression-free survival rate compared to chemotherapy alone,” AIPAC principal investigator Hans Wildiers, of the University Hospitals Leuven in Belgium, said in a press release. “Hormone receptor positive breast tumors represent the majority of metastatic breast cancer patients and…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments